Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
about
Biology, Therapy and Implications of Tumor Exosomes in the Progression of MelanomaMRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours.Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging.Current Development Status of MEK Inhibitors.Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases.18F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma.The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.Regulating the cytoprotective response in cancer cells using simultaneous inhibition of Hsp90 and Hsp70.Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas.
P2860
Q28070187-A7EB0F40-C145-44DD-84AC-43B6B4AD0537Q30881669-E9E28F8B-7067-4BF9-836A-231927B3D920Q35275024-337F24B4-6C0D-482C-A38B-E2E88B4DC5CAQ35677936-C0BD8CD5-55EE-43CF-8D60-02B32A092142Q36544152-5748EC3D-F911-4ED1-B8D5-BC62838C2B6FQ41423088-53A75BA0-E4A3-43F2-BE80-A338A969EB8DQ47735535-63AF494F-8544-428E-A692-E4BB234D8BECQ48246087-20F05E58-FD86-4FFE-B8B4-6D9EB476EE35Q49770136-CD436CB4-651D-496C-9458-0283B0ED082BQ52991636-91C11ECC-AAE2-4551-9363-7CAEE5494E39Q53663668-E1F76682-CC5E-4ADE-B5B8-55776EC92B06Q55261716-D2798AC2-A289-4C59-BB34-692031DE685F
P2860
Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acute tumour response to the M ...... vasive diffusion-weighted MRI.
@en
Acute tumour response to the M ...... vasive diffusion-weighted MRI.
@nl
type
label
Acute tumour response to the M ...... vasive diffusion-weighted MRI.
@en
Acute tumour response to the M ...... vasive diffusion-weighted MRI.
@nl
prefLabel
Acute tumour response to the M ...... vasive diffusion-weighted MRI.
@en
Acute tumour response to the M ...... vasive diffusion-weighted MRI.
@nl
P2093
P2860
P50
P356
P1476
Acute tumour response to the M ...... nvasive diffusion-weighted MRI
@en
P2093
J Halliday
M Beloueche-Babari
S Walker-Samuel
P2860
P2888
P304
P356
10.1038/BJC.2013.456
P407
P577
2013-08-13T00:00:00Z